In our mice that had established CKD, a single dose of anti-RANKL effectively mitigated high bone turnover and reduced the aberrant intracortical remodeling indicating the potential therapeutic benefits of systemic RANKL blockage even after the development of CKD-induced bone alterations. This evidence concerns the gene TNFSF11 and chronic kidney disease.